NEW YORK (360Dx) – Proteomics startup Seer Biosciences is developing a nanotechnology-based platform that it says will enable rapid, deep, and inexpensive proteome-scale analyses.

The South San Francisco, California-based company is focused on early detection of diseases in oncology and neurology and plans to launch its first product as a laboratory-developed test in 2021, said Omid Farokhzad, Seer's founder and CEO.

To support these efforts, the company has raised $36 million in funding through Series A and B rounds led by Maverick Ventures and Invus, respectively.